The Prognosis of Patients After PCI：a Multi-center Study in China

Launched by WUHAN UNION HOSPITAL, CHINA · Nov 6, 2022

Keywords

ClinConnect Summary

This clinical trial is studying how a specific blood marker called hsCRP (high-sensitivity C-reactive protein) affects the health of patients who have undergone a procedure called percutaneous coronary intervention (PCI) for coronary heart disease (CAD). Researchers believe that measuring hsCRP levels can help understand the risk of serious heart and brain problems after the PCI. The study aims to follow patients for one year to see how changes in hsCRP levels relate to their health outcomes.

To participate in this trial, individuals must be between 18 and 80 years old, have been hospitalized for coronary heart disease, and have completed their PCI procedure. It's important to note that people with certain medical conditions, such as infections, immune diseases, or those who are pregnant, are not eligible to take part. Participants can expect regular check-ins and blood tests over the course of the study to monitor their hsCRP levels and overall health. This research may help improve future care for patients with coronary heart disease in China.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Participants who understand and sign the informed consent voluntarily;
• • Age ≥ 18 years old and ≤ 80 years old, regardless of sex;
• • The hospitalized patients with coronary heart disease undergoing PCI;
• • Complete all planned PCI during hospitalization.
• Exclusion Criteria:
• • Acute, chronic or recurrent infectious diseases;
• • Immune diseases or immune-related diseases;
• • Long-term use of non-steroidal anti-inflammatory drugs, hormones, immunomodulatory and chemotherapy drugs;
• • Pregnant women, lactating women or women of childbearing age who do not use effective contraceptive measures;
• • The researchers determined that other conditions in which the patient was not suitable to participate in the clinical trial.